Find in Library

No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies

oleh: Johannes Griss, Gudrun Ratzinger, Julia‐Tatjana Maul, Wolfgang Weger, Diamant Thaçi, José Manuel Carrascosa, Constanze Jonak